We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 535.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 521.00 | 524.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 535.00 | GBX |
Silence Therapeutics (SLN) Share Charts1 Year Silence Therapeutics Chart |
|
1 Month Silence Therapeutics Chart |
Intraday Silence Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/11/2021 | 19:53 | Silence Therapeutics (the old SR Pharma) | 50,424 |
| 08/8/2019 | 05:43 | Lets Short This Duffer Out Of Business | 704 |
| 06/10/2016 | 08:04 | Gower Productions Presents ....."PREDICTA BID" | 52 |
| 05/10/2016 | 19:29 | port | - |
| 29/5/2013 | 09:32 | Silence Therapeutics - news and views | 1,412 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 16/11/2021 20:01 by 1gw frndlyfire - no advice intended here - please check with your own provider/advisor - but my understanding is that SLN ADS's can be bought today in an ISA (subject to the provider having that particular ADS on its platform) but once SLN delists from AIM that will not be possible as the underlying investment (SLN ordinary shares) will be unlisted. And any SLN ADS's you have in an ISA after delisting of the underlying investment may have to be removed from the ISA.volsung - yes my HL portfolio looks as though it has taken quite a hit with the removal of price on the SLN holding. Tomorrow is the deadline for CREST holders (such as HL) to get their paperwork to BNY Mellon for deposit of ordinary shares for delivery of ADSs. Presumably we now have a few days to wait until the ADSs get credited to our accounts. |
Posted at 09/11/2021 13:26 by 1gw Dicerna trumping SLN in terms of programs overall and expectation for programs entering the clinic (4 per year entering clinic over next 2 years for DRNA vs 2-3 INDs per year from 2023 for SLN), but seen from the broader perspective of RNAi coming of age, it's an exciting time."Between Dicerna and our collaborative partners, we have 16 programs in preclinical or clinical development as well as more than 20 discovery-stage programs. Given the breadth of these activities, we expect new programs to be entering the clinic, on average, one per quarter over the next two years and potentially beyond that at a similar rate. " |
Posted at 04/11/2021 14:06 by lyncom When I asked AJ Bell if I could buy & sell SLN ADS shares in my SIPP, I got the following reply:'Please be advised that you would be able to sell the ADS shares following the conversion but you would not be able to purchase anymore as we do not permit the purchase of ADS's in a SIPP where the underlying stock is not on an HMRC recognised exchange.' As I do not trade, this is not a major problem but it is frustrating that once I do decide to sell it looks like its bye bye SLN. I suppose AJ Bell knows whats its talking about but I was under the impression that NASDAQ was a recognised exchange as it is on: as follows: 'Recognised stock exchanges A stock exchange in the USA is a recognised stock exchange for UK tax purposes if it meets the following: “Any exchange registered with the Securities and Exchange Commission of the United States (SEC) as a national securities exchange under section 6 of the Securities Exchange Act of 1934 is a recognised stock exchange for UK tax purposes”. The recognised stock exchanges in United States of America are: BATs Exchange Inc Boston Stock Exchange Chicago Board Options Exchange Chicago Stock Exchange International Securities Exchange National Stock Exchange New York Stock Exchange NYSE MKT NYSE Arca NASDAQ OMX PHLX NASDAQ Listed status of markets on the stock exchange Stock exchange Listed Not listed BATs Exchange Inc Main markets Boston Stock Exchange Main markets Chicago Board Options Exchange Main markets Chicago Stock Exchange Main markets International Securities Exchange Main markets National Stock Exchange Main markets New York Stock Exchange Main markets NYSE MKT Main markets NYSE Arca (Some Exchange Traded Funds previously traded on the American Stock Exchange have moved to this market) Securities listed on the Main markets Over the counter transactions NASDAQ OMX PHLX (Formerly the Philadelphia Stock Exchange) Main markets NASDAQ NASDAQ Global NASDAQ Global Select NASDAQ Capital Market' I'm confused - any views? |
Posted at 02/11/2021 14:52 by 1gw Interactive Investor put out a note late yesterday afternoon (at least to me) saying that they expected SLN ADS's not to be eligible to be held in an ISA or a SIPP, so I suspect there's been a bit of panic selling this morning.From a bit of googling, and then from talking to II and Hargreaves Lansdown, I think II may be right in general about ISAs (i.e. it looks to me as though SLN ADS's perhaps can't be held in any ISA after the delisting of the underlying SLN ordinary shares) but for SIPPs I think they're just describing the II SIPP policy rather than the requirements of the tax legislation. It's a shame because I had already sold most of my shares in my Barclays ISA (which doesn't allow you to hold US shares) and bought them back in my Interactive Investor ISA account, thinking that would be able to hold the SLN ADS's. So today I have been buying more in my HL SIPP and selling the remaining shares in my 2 ISA accounts. I went to the General Meeting yesterday, which was a fantastic opportunity to talk to the directors as I seemed to be the only shareholder (other than directors and advisors) there (second time with SLN I have been in this position). I have to say I came away encouraged about both the business and the delisting. Since the general meeting I have been in touch with SLN IR about the II note, hoping that they might be able to find a workaround. But having googled the ISA rules, I suspect they can't which is why I have sold out of my ISA positions and bought the shares in my SIPP. This is offered in good faith as my understanding of what has happened, but no advice is intended. Please check with your own providers/advisors about your own accounts. I would be interested in anyone else's experience for comparison, particularly around ISA and SIPP holdings. |
Posted at 21/10/2021 15:53 by 1gw Anyone else watch that? A couple of other things that came out for me (as I heard it) were:o For the 3 SLN124 indications already identified, they estimate peak sales potential of $3bn-$5bn, with the latest indication (PV) having a relatively big market - so SLN124 becoming a much more interesting asset. o They expect to be able to go into P2 for SLN360 based largely on the SAD results (due in 1Q), rather than have to wait for the later MAD results before engaging the FDA on P2 design. Meanwhile, Yahoo! Finance shows just 9 ADSs traded in SLN on the Nasdaq listing. |
Posted at 14/10/2021 15:09 by 1gw Another potential near-term catalyst (apart from the R&D day and a new licensing deal) is an announcement around IND progress for SLN501, the Mallinckrodt-licenseThey triggered a milestone in April when they said: "The milestone relates to pre-clinical development work on the SLN500 C3 targeting program, highlighting the successful ongoing collaboration between the two companies. Silence continues to work with Mallinckrodt to progress Investigational New Drug (IND) enabling studies for SLN501, the first nominated product candidate in the SLN500 program, this year." In the meantime, ARWR has made it clear that it is also targeting C3, so that should incentivise MNK and SLN to keep the pace up on SLN501: |
Posted at 14/10/2021 14:17 by 1gw Just on your "deal" point, I read that as M&A first time round, but on the licensing side I think something is certainly possible before the next clinical read-out (in 1Q). Takeda would be the obvious one, if they come back to license the technology having reviewed the data from the SLN research evaluation and looked at whatever other technology options they have for the target that was being evaluated. Rothera has in the past hinted at a bigger deal with Takeda than just that target, but following the completion of the research evaluation without news of a deal my expectations have cooled a bit.On one of the recent presentations I think Rothera referred to new "inbound interest" following the disclosure of the SLN124 clinical data, so there could be other licensing discussions on the go as well, although perhaps not for SLN360 (where it seems they want to take it at least through Phase 1 as a wholly-owned asset) or SLN124 (where I think they plan to take it further than SLN360 given its more niche application). |
Posted at 07/10/2021 17:23 by 1gw Did you see Dirk just opined on twitter that SLN was "still too small"? He sees limited competition for gene knock-down targets meaning he thinks there's a monopoly/duopoly available for most targets from the 4 big players. We can hope that Takeda or someone else makes a move for SLN at some point, but maybe not likely until at least after we see the topline SLN360 SAD data - and realistically I think SLN would want to demonstrate its ability to do the "2-3 INDs per year from 2023" before seriously entertaining a bid approach.I've got SLN down to below 10% of my portfolio now (still 4th biggest holding), which feels more appropriate as we head towards clinical data and the volatility that comes with that. I'd like to buy some more before the R&D day (21st Oct) if the price stays down here but a number of my bigger holdings are looking a bit beaten up at the moment so it feels a bit difficult to free up much in the way of funds to add to SLN. I hope they will reveal some of the previously undisclosed targets/undisclosed indications. They have been asked about these at one of the recent presentations but didn't give any indication that they would be revealing anything in the near term, so it may be more about SLN124 and SLN360 and I hope that's not just a rehash of previously-released data. Recent presentations have been anything but exciting for anyone who has followed the company for a while - very much the same story as they've given previously as far as I can tell. |
Posted at 18/12/2020 09:49 by 1gw I've sold some in the 470's over the last few days, and may sell some more. I'm in year-end portfolio assessment mode and I have decided to bank some profit here on my 2nd-largest position after a spectacular year generally and a good one on SLN.If I look at all my buys and sells in SLN over the year, I've been relatively busy, putting through 116 transactions over 41 days. I've ended up losing a few % overall (average sell price / average buy price) due to being over optimistic about the near-term share price prospects after the Astrazeneca deal announcement and ahead of the Nasdaq listing. That loss is far outweighed (at this point) by the mark-to-market gain on my remaining position. Looking ahead to next year, I remain optimistic that it will be another good year, with particular hopes for a Takeda licensing deal early in the year and some good clinical read-outs from SLN124. The really big event for the year I think will come later with the first read-outs on SLN360. But this is biotech and as SLN is now a clinical biotech, there is the risk of major price downside should clinical readouts disappoint (e.g. SAE's, off-targeting, lower than expected knockdown), and that is a factor in my decision to take some profits here. |
Posted at 10/10/2020 13:39 by 1gw I can't speak for anyone else, but I own as many shares as I've ever owned. I first bought in in May 2016 (at 130p) and at the end of each calendar year I have owned more shares than at the end of the previous year each time with the exception of end-19 when I had reduced a bit as a result of profit-taking. Share prices have been:130p May'16 100p End-2016 194p End-2017 52p End-2018 350p End-2019 400p Now So to date patience has paid off, even if anyone who managed to sell out at the peak would be happy right now. My frustration comes in part from thinking that the shareprice would have reacted better to the US listing, although if you look at say a 3-month chart of SLN vs ARWR and DRNA, SLN has done OK in relative terms. What has perhaps happened is that the US listing premium was reflected in SLN holding its price when the others were falling, and by the time we got to the actual listing that premium was pretty much fully built in. I've done very well (so far) on buying and selling ARWR, DRNA and ABUS and that also adds a bit to my current frustration with the SLN price. I also find the "artifical" prices frustrating. When the bid has popped up and I've tried to sell some, there seems to be no meaningful quantity available on my platforms at the apparent bid. And vv sometimes on the offer when I've tried to buy. It feels to me that there's not much depth to the bid or the offer and liquidity is perhaps worse now than before the US listing. Whether that means that something is brewing and some of the normal liquidity providers are now "inside" and so unable to trade, or whether it is just that attention is focused elsewhere in biotech (or other sectors) I have no idea. But the bull story hasn't changed for me, except perhaps that clinical risk is looming a bit larger. Now that we've had such a good year (deals, listing, first dosing, new CEO) we're perhaps in a bit of a lull ahead of the next deal (Takeda most likely?) and first clinical read-outs - and maybe that is making it easier for someone to mess around with the price, or perhaps some are taking profits. I have tried to sell some (without much success given the apparent poor liquidity) but overall I'm happy to keep a big position in the expectation that the price will recover in due course. As always, no advice intended. Please DYOR, this is early-stage biotech. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
